These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37655058)

  • 21. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.
    Alhadab A; Almarhoon A; AlAlwan A; Hammo A
    Saudi J Gastroenterol; 2024 Apr; ():. PubMed ID: 38597337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 24. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
    Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
    Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
    J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease.
    Suárez Ferrer C; Arroyo Argüelles J; Rueda García JL; García Ramírez L; Martin Arranz E; Sánchez Azofra M; Poza Cordón J; Noci Belda J; Martin-Arranz MD
    J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.
    Oh K; Hong HS; Ham NS; Lee J; Park SH; Yang SK; Yoon H; Kim YS; Choi CH; Ye BD;
    Intest Res; 2023 Jan; 21(1):137-147. PubMed ID: 36751044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
    Sedano R; Guizzetti L; McDonald C; Jairath V
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1497-1498.e1. PubMed ID: 32763479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
    Lee CK; Moon W; Chun J; Kim ES; Kim HW; Yoon H; Kim HS; Lee YJ; Choi CH; Jung Y; Park SC; Song GA; Lee JH; Jung ES; Kim Y; Jung SY; Choi JM; Ye BD
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39096895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
    Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
    Tursi A; Mocci G; Scaldaferri F; Napolitano D; Maresca R; Pugliese D; Semprucci G; Savarino E; Cuomo A; Donnarumma L; Bodini G; Pasta A; Maconi G; Cataletti G; Pranzo G; Rodinò S; Sebkova L; Costa F; Ferronato A; Gaiani F; Marzo M; Luppino I; Fabiano G; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Grossi L; Serio M; Scarcelli A; Lorenzetti R; Allegretta L; Chiri S; Grasso G; Antonelli E; Bassotti G; Spagnuolo R; Luzza F; Fanigliulo L; Rocco G; Sacchi C; Zampaletta C; Rocchi C; Bolognini L; Bendia E; Bianco MA; Capone P; Meucci C; Colucci R; Tonti P; Neve V; Della Valle N; Felice C; Pica R; Cocco A; Forti G; Onidi FM; Usai Satta P; Checchin D; Gravina AG; Pellegrino R; Picchio M; Papa A
    Expert Opin Biol Ther; 2024; 24(1-2):101-109. PubMed ID: 38250818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
    Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
    Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
    Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
    J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
    Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
    J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience.
    Jeffrey AW; Abu-Rgeef R; Picardo S; Menon S; So K; Venugopal K
    Ann Gastroenterol; 2023; 36(5):549-554. PubMed ID: 37664232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.